PA5-80713

antibody from Invitrogen Antibodies

Targeting: IGSF5 JAM4

Western blot (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-80713

Provider

Invitrogen Antibodies

Product name

IGSF5 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

This product is preservative free. It is recommended to add sodium azide to avoid contamination (final concentration 0.05%-0.1%).

Concentration

1 mg/mL

References

Submitted references

Identification of Immune-Related Prognostic Biomarkers Associated with HPV-Positive Head and Neck Squamous Cell Carcinoma.

Chen Y, Nie J, Li X, Fan T, Deng X, Liang D, Song G
Journal of immunology research 2021;2021:6661625

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of IGSF5 in Lane A: 293 Whole Cell Lysate (30 µg). Samples were probed using a IGSF5 Polyclonal Antibody (Product # PA5-80713) at a 1:500 dilution, followed by a Goat Anti-Rabbit IgG (H+L), Dylight 800 Secondary Antibody at a 1:10000 dilution. Western blot was performed under reducing conditions. Predicted band size:45 kDa. Observed band size:45 kDa.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western Blot using IGSF5 Polyclonal Antibody (Product # PA5-80713) at 1:500 dilution. Lane A: 293 Whole Cell Lysate. Lysates/proteins at 30 μg per lane. Secondary Goat Anti- RabbitIgG H&L (DyLight™ 800) at 1:10,000 dilution. Developed using the Odyssey technique. Performed under reducing conditions. Predicted band size: 45 kDa. Observed band size: 45 kDa.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 10 Overexpression of IGSF5 inhibits the proliferation of HNSCC cells. (a) IGSF5 had lower expression in HNSCC samples than in matched normal tissues from the TCGA database (normal = 44, tumor = 519). (b) IGSF5 in HPV-positive HNSCC tissues from the GSE65858 cohort was upregulated compared with that in HPV-negative tissues. (c) The expression of IGSF5 was detected by Western blot, and cells transfected with the IGSF5 overexpression plasmid differed significantly between the IGSF5 overexpression (pCDNA-IGSF5) and control (vector) groups in Hep-2 and TU212 cells. GAPDH was used as an internal control. (d) Reduction in the proliferation ability of pCDNA-IGSF5 Hep-2 and TU212 cells compared with the control (vector) cells by the CCK8 assay. (e, f) Reduction in colony formation ability of pCDNA-IGSF5 Hep-2 and TU212 cells compared with the control (vector) cells by a colony formation assay. The bar graph indicates the number of colonies. (g, h) Cell apoptosis of pCDNA-IGSF5 Hep-2 and TU212 cells compared with the control (vector) was analyzed by flow cytometry. The rate of cell apoptosis is shown in the graphs. The results are presented as the mean +- s.d. and are representative of at least three independent experiments. * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. ns: p > 0.05.